Article and Video CATEGORIES
There's a really helpful resource for patients, developed by several leading experts in EGFR-based therapy and specifically the very common skin toxicity associated with EGFR inhibitors like iressa, tarceva, erbitux, and some others. I've already described some early ideas about rash management (prior post) and a more recent medical education program video on the same subject (prior post here). This is a summary article (here) published in the free oncology journal The Oncologist, but I think that more important than the brief review article are the summary poster and brochure for patients. Rather than recapitulate the content myself, I'll just reproduce them for you to view here (click on any of these images to enlarge).
Here's the poster (also available as a pdf here):
The brochure for patients is below (or pdf here):
These materials are also offered free, so if you find them helpful, you may want to speak with your oncologist or another health educator and point them to the direction of this form.
In the meantime, it's good to see some real protocols for management become established and now widely available.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…